Events

2013 News Releases



Webcast ImageWebcast
Q1 2017 Rigel Pharmaceuticals Inc. Earnings Conference Call  (Live)
May 2, 2017 at 2:00 p.m. PT
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/05/13Rigel to Present at Oppenheimer Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is scheduled to present a company overview at the Oppenheimer 24th Annual Healthcare Conference in New York City on Wednesday, December 11th at 2:10 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minut... 
Download PDFPrinter Friendly Version
11/05/13Rigel Announces Third Quarter 2013 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2013. For the third quarter of 2013, Rigel reported a net loss of $23.8 million, or $0.27 per share, compared to a net loss of $25.5 million, or $0.36 per share, in the same period of 2012. Weighted average shares outstanding for the third quarters of 2013 and 2012 were 87.4 million and 71.6 million, res... 
Download PDFPrinter Friendly Version
10/24/13Rigel Provides Pipeline Update
Path Forward Clear for Fostamatinib, Ends for R333 SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.   R333 Update Rigel announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), di... 
Download PDFPrinter Friendly Version
09/06/13Rigel to Present at Stifel Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel 2013 Healthcare Conference in Boston, MA on Thursday, September 12th at 1:30 p.m. ET. The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webca... 
Download PDFPrinter Friendly Version
09/05/13Rigel To Focus On ITP, DLE And Dry Eye
Strategy Provides Multiple Paths to Phase 3/NDA in Next 2-3 Years SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura (ITP) pending discussions with regulatory agencies. Rigel believes that a... 
Download PDFPrinter Friendly Version
08/26/13Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study.  The primary endpoint was the change in pre-bronchodilator FEV1 (a measure of lung function) from baseline to dosing completion at Week 8, comparing active doses to placebo... 
Download PDFPrinter Friendly Version
08/06/13Rigel Announces Second Quarter 2013 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2013. (Logo:  http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) For the second quarter of 2013, Rigel reported a net loss of $22.8 million, or $0.26 per share, compared to a net loss of $24.7 million, or $0.35 per share, in the same period of 2012. Weighted average shares outstanding for the second quar... 
Download PDFPrinter Friendly Version
06/04/13Rigel Will Resume Responsibility for Fostamatinib Program
Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3 SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).  In the OSKIRA-2 study o... 
Download PDFPrinter Friendly Version
05/22/13Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
Two Partnered Oncology Programs to Initiate Clinical Trials SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease.  The other two programs are aimed at oncology targets and are being conducted by corporate partner... 
Download PDFPrinter Friendly Version
05/07/13Rigel Announces First Quarter 2013 Financial Results
SOUTH SAN FRANCISCO, Calif., May 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively. There ... 
Download PDFPrinter Friendly Version
04/05/13AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
SOUTH SAN FRANCISCO, Calif., April 5, 2013 /PRNewswire/ -- AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA).  OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score). In the OSKIRA-1 study, fostamatinib ac... 
Download PDFPrinter Friendly Version
03/05/13Rigel Announces Fourth Quarter and Year End 2012 Financial Results
SOUTH SAN FRANCISCO, Calif., March 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2012. For the fourth quarter of 2012, Rigel reported a net loss of $25.5 million, or $0.30 per share, compared to a net loss of $25.8 million, or $0.36 per share, in the fourth quarter of 2011. Weighted average shares outstanding for the fourth quarter of 2012 and 2011 were 85.3 million and 71.2 million, respec... 
Download PDFPrinter Friendly Version
02/28/13Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will participate at two upcoming investor conferences. Details of the events are as follows: Cowen and Company 33rd Annual Health Care Conference  Date: Wednesday, March 6 at 8:40 a.m. ET  Location: Boston, MA  Speaker: Ryan Maynard ... 
Download PDFPrinter Friendly Version
02/07/13Rigel to Present at BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 15th Annual BIO CEO & Investor Conference in New York City on Monday, February 11th at 10:00 a.m. ET. To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several min... 
Download PDFPrinter Friendly Version
01/03/13Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation
R348 for Chronic Dry Eye Initiates Clinical Trial SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present an update on the company's product portfolio at the J.P. Morgan Healthcare Conference in San Francisco on January 7, 2013 at 1:30pm Pacific time (see webcast details below).  In December 2012, Rigel initiated a Phase 1 clinical s... 
Download PDFPrinter Friendly Version